Effect of antidiabetic therapy on TNF-α, IL-18, IL-23 and IL-35 levels in T2DM patients with coincidental Helicobacter pylori infection

• Main Authors: Adel Abdel-Moneim, Sanaa M. Abd El-Twab, Ahmed Nabil, Salma A. El Kazafy
• Format: Article
• Language: English
• Published: Taylor & Francis Group 2020-01-01
• Series: Journal of Taibah University for Science
• Subjects: h. pylori; type 2 diabetes; tnf-α; il-18; il-23; il-35
• Online Access: http://dx.doi.org/10.1080/16583655.2020.1824669

This study aimed to evaluate the relationship between tumour-necrosis factor-alpha (TNF-α), interleukin (IL)-18, IL-23, IL-35 and Heilcobacter (H) pylori infection with T2DM. A total of 25 healthy subjects and 102 confirmed T2DM patients were enrolled in this study. Diabetic patients were subdivided into six groups according to antidiabetic therapy. Diabetic non-treated patients exhibited a significant elevation in H. Pylori- Ig-G, TNF-α, IL-18, and IL-23 levels, but a noticeable decrease in IL-35 expression was observed compared to healthy controls. Antidiabetic therapy induced a significant decrease in the level of glycosylated hemoglobin (HbA1c), TNF-α, IL-18 and IL-23, while IL-35 expression was upregulated compared to diabetic controls. The results exhibited a positive correlation between H. pylori and HbA1c%, TNF-α, IL-18, and IL-23 values, and also between HbA1c% and TNF-α, IL-18 and IL-23 levels. Therefore, antidiabetic therapy decreases significantly the hyperglycemic state and circulating level of inflammatory cytokines which reflects their potential anti-inflammatory effects.